Covestor Ltd purchased a new position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 305 shares of the biotechnology company’s stock, valued at approximately $81,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Confluence Wealth Services Inc. purchased a new position in shares of Repligen in the 4th quarter worth $27,000. Assetmark Inc. acquired a new stake in Repligen in the 3rd quarter valued at $49,000. Sageworth Trust Co of South Dakota acquired a new stake in Repligen in the 4th quarter valued at $46,000. UMB Bank N A MO acquired a new stake in Repligen in the 4th quarter valued at $59,000. Finally, Fieldpoint Private Securities LLC grew its stake in shares of Repligen by 36.8% during the third quarter. Fieldpoint Private Securities LLC now owns 260 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 70 shares in the last quarter. 86.82% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:RGEN opened at $154.68 on Wednesday. The company has a market capitalization of $8.42 billion, a price-to-earnings ratio of 61.14 and a beta of 0.98. Repligen Co. has a one year low of $137.21 and a one year high of $327.32. The stock has a 50-day simple moving average of $166.13 and a 200 day simple moving average of $207.72.
In other Repligen news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total value of $396,060.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.10% of the company’s stock.
Several analysts have recently weighed in on the company. StockNews.com assumed coverage on Repligen in a research note on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating and set a $190.00 target price for the company. in a research note on Monday, February 21st. Craig Hallum lowered their target price on Repligen from $286.00 to $274.00 in a research note on Thursday, April 28th. Finally, SVB Leerink lowered their target price on Repligen from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, February 18th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $285.57.
Repligen Profile (Get Rating)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- Get a free copy of the StockNews.com research report on Repligen (RGEN)
- 3 Small Caps With Big Return Potential
- Take-Two Interactive (NASDAQ: TTWO) Moves Back From The Brink
- The Weber, Inc Growth Story Goes Up In Smoke
- Roku Stock is Repricing and Resetting Itself
- The Institutions Are Capping Gains In Take-Two Interactive
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.